| Attribute |
Value |
References |
| Symbol |
CIDEB |
|
| Name |
Cell Death-Inducing DFFA-Like Effector B |
|
| Chromosome |
14q12 |
|
| NCBI Gene ID |
27151 |
|
| UniProt ID |
Q9BQN5 |
|
| OMIM |
618233 |
|
CIDEB (Cell Death-Inducing DFFA-Like Effector B) is a lipid droplet-associated protein primarily expressed in the liver and involved in lipid droplet formation, hepatic lipid metabolism, and regulation of cell death pathways. While not classically associated with neurodegeneration, emerging research suggests that hepatic lipid metabolism may influence brain health through the liver-brain axis, with implications for neurodegenerative diseases.
CIDEB (Cell Death-Inducing DFFA-Like Effector B) is a member of the CIDE (Cell Death-Inducing DFFA-Like Effector) family of proteins, which also includes CIDEa and CIDEc. These proteins are characterized by a unique CIDE domain and play crucial roles in lipid droplet biology.
Lipid droplets are dynamic organelles that store neutral lipids (triglycerides and cholesterol esters) in cells. They function as:
- Energy reserves
- Membrane precursors
- Signaling platforms
- Storage compartments for lipotoxic species
CIDEB localizes to the surface of lipid droplets and regulates their formation, size, and distribution. Unlike CIDEa (predominantly in adipose tissue) and CIDEc (in mammary gland), CIDEB is primarily expressed in the liver.
- Lipid Droplet Fusion: CIDEB promotes the fusion of small lipid droplets into larger droplets, regulating droplet size distribution
- Lipid Storage: The protein enhances triglyceride storage in lipid droplets, protecting cells from lipotoxicity
- Lipid Mobilization: CIDEB also participates in lipid mobilization during periods of metabolic demand
The CIDE family proteins contain a CIDE-N domain at the N-terminus and a CIDE-C domain at the C-terminus. These domains mediate protein-protein interactions and lipid droplet targeting.
In hepatocytes, CIDEB:
- Regulates hepatic lipid droplet accumulation
- Protects against lipotoxicity from excess free fatty acids
- Contributes to very-low-density lipoprotein (VLDL) assembly
- Modulates hepatic lipid homeostasis
CIDEB is primarily associated with hepatic lipid metabolism disorders:
-
Non-Alcoholic Fatty Liver Disease (NAFLD)
- CIDEB expression is altered in NAFLD
- The protein contributes to hepatic triglyceride accumulation
- May protect against lipotoxicity in early disease stages
-
Non-Alcoholic Steatohepatitis (NASH)
- Dysregulated lipid droplet function contributes to inflammation
- CIDEB may play a role in disease progression
-
Hepatic Insulin Resistance
- Lipid accumulation in liver causes insulin resistance
- CIDEB-mediated lipid droplet regulation affects insulin signaling
The liver-brain axis represents a novel mechanism linking hepatic function to brain health:
Peripheral lipid metabolism affects brain health through multiple pathways:
- Blood-brain barrier (BBB) lipid transport: Specific lipids cross the BBB and influence neuronal function
- Circulating lipoprotein particles: Liver-derived lipoproteins deliver lipids to the brain
- Lipotoxicity from circulation: Elevated circulating lipids may damage cerebral vasculature
¶ 2. Liver Disease and Dementia Risk
Epidemiological studies show associations between:
- Non-alcoholic fatty liver disease (NAFLD) and increased dementia risk
- Cirrhosis and cognitive impairment (hepatic encephalopathy)
- Elevated liver enzymes and Alzheimer's disease risk
While direct evidence linking CIDEB to neurodegeneration is limited, several hypothetical mechanisms could connect hepatic CIDEB function to brain health:
- Reduced lipid clearance: Impaired CIDEB function could reduce hepatic clearance of circulating lipids, increasing neurotoxic lipid delivery to the brain
- Altered lipoprotein production: Changes in hepatic lipoprotein production affect brain lipid supply
- Systemic inflammation: Liver inflammation increases circulating inflammatory mediators that access the brain
- Impaired autophagy: Lipid droplet turnover is linked to autophagy, a process impaired in neurodegeneration
CIDEB plays a role in:
- Atherosclerosis development
- Foam cell formation
- Vascular lipid accumulation
These cardiovascular effects may indirectly affect cerebral perfusion and neurodegenerative risk.
CIDEB is expressed primarily in:
- Liver (hepatocytes) — highest expression
- Kidney (lower expression)
- Brain — very low expression
In the brain, the minimal expression suggests that any brain-related effects would likely be mediated through peripheral hepatic function rather than direct neuronal effects.
- Lipid droplet surface: Primary localization
- Endoplasmic reticulum: Secondary localization
- Cytoplasm: Diffuse distribution
CIDEB interacts with:
- CIDE family members: CIDEa, CIDEc (heterodimerization)
- Perilipin family: Lipid droplet coating proteins
- ATGL (Adipose Triglyceride Lipase): Lipid mobilization
Despite its name, CIDEB's role in cell death is complex:
- May promote apoptosis in certain contexts
- Can protect against cell death via lipid droplet sequestration
- Regulates caspase-independent cell death pathways
¶ Mermaid Diagram: CIDEB Functions and Liver-Brain Axis
flowchart TD
A["CIDEB Gene<br/>14q12"] --> B["CIDEB Protein"]
B --> C["Lipid Droplet<br/>Regulation"]
B --> D["Hepatic Lipid<br/>Metabolism"]
C --> E["Triglyceride<br/>Storage"]
C --> F["Lipid Droplet<br/>Fusion"]
D --> G["VLDL<br/>Assembly"]
D --> H["Lipotoxicity<br/>Protection"]
E --> I["Liver Function"]
G --> I
I --> J["Liver-Brain Axis"]
J --> K["Circulating Lipids"]
J --> L["Lipoprotein<br/>Production"]
J --> M["Systemic<br/>Inflammation"]
K --> N["Brain Health"]
L --> N
M --> N
N --> O["Neurodegeneration<br/>AD/PD Risk"]
Modulating CIDEB or lipid droplet function could influence neurodegenerative risk:
- Lipid droplet modulators: Enhance lipid sequestration to reduce lipotoxicity
- Liver-targeted therapeutics: Improve hepatic lipid clearance
- Anti-inflammatory agents: Reduce liver-derived systemic inflammation
- Diet: Reduce saturated fat intake to decrease hepatic lipid burden
- Exercise: Enhances hepatic lipid oxidation
- Weight management: Reduces NAFLD risk
- Investigate CIDEB expression in liver of AD/PD patients
- Study the relationship between NAFLD and neurodegeneration biomarkers
- Explore liver-targeted interventions for neuroprotection
-
CIDEB and lipid droplets: The protein is a key regulator of hepatic lipid droplet formation and size, protecting against lipotoxicity.
-
Liver-brain axis: The liver affects brain health through lipid metabolism, lipoprotein production, and systemic inflammation.
-
NAFLD and dementia: Epidemiological evidence links fatty liver disease to increased dementia risk.
-
Lipotoxicity in neurodegeneration: Circulating lipids may contribute to neurotoxicity and disease progression.